# OPRA (NCT02008656)

> Trial Evaluating 3-year Disease Free Survival in Patients With Locally Advanced Rectal Cancer Treated With Chemoradiation Plus Induction or Consolidation Chemotherapy and Total Mesorectal Excision or Non-operative Management

No report yet. It can be ordered.

- Drugs tested: oxaliplatin plus fluorouracil plus leucovorin; oxaliplatin plus capecitabine
- Indication: locally advanced rectal cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02008656
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Memorial Sloan Kettering Cancer Center
- Conditions: Rectal Cancer
- Interventions: Oxaliplatin (OXAL); 5-Fluorouracil (5-FU); Leucovorin; Capecitabine (Xeloda®); intensity modulated radiotherapy (IMRT); Quality of Life Questionnaires; DRE-Endoscopy
- Enrollment: 358
- Primary outcome: disease-free survival (DFS)

## Indexed commentary on OPRA so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 132 posts on X
- 23 YouTube videos
- 22 podcast episodes
- 2 videos on X

## Order

Deep, $1,950 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=opra-nct02008656

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT02008656", "email": "<work email>"}; the inbox owner confirms by the emailed link.